In 2014, Alzheimer Europe had an audited income of EUR 1,163,599.24 of which EUR 618,472.58 (53.15%) were for the organisation’s core activities (including the organisation’s Dementia Ethics Network) and EUR 545,126.66 (46.85%) were for the organisation’s annual conference, corporate affairs activities and other projects.

Funding of core activities (EUR 618,472.58)

In 2014, the core funding of Alzheimer Europe was composed as follows:

• EUR 365,986.09 (59.18%) from public funding,
• EUR 118,500.00 (19.16%) from foundations and other non-profit organisations,
• EUR 77,289.74 (12.50%) from member organisations,
• EUR 40,700 (6.58%) from corporate sources,
• EUR 998.56 (0.16%) from private individuals,
• EUR 558.22 (0.09%) from bank interest and similar,
• EUR 14,439.97 (2.33%) from other sources.

Public funding

In 2014, the breakdown of public funding totalling EUR 365,986.09 can be broken down as follows:

• Alzheimer Europe received EUR 285,168 as an operating grant from the European Commission, EUR 24,652.79 for its participation in the PredictND project, EUR 14,709.92 for its participation in the EMIF project, EUR 10,630.07 for its participation in the NILVAD project, EUR 10,162.51 for its participation in the Aetionomy project, EUR 9,124.50 for its participation in the PACE project, EUR 6,544.98 for its participation in the PharmaCog project, and EUR 4,993.32 for its participation in the AFE-Innovnet project.

Foundations and organisations

The EUR 118,500 which Alzheimer Europe received in 2014 from foundations and other non-profit organisations can be broken down as follows:

• EUR 87,000 as direct support from Fondation Alzheimer, Luxembourg,
• EUR 31,500 in donated time by experts involved in the ethical work and comparison of national dementia strategies of Alzheimer Europe (at EUR 300 per day).

Funding from member organisations

In 2014, the EUR 77,289.74 funding from member organisations can be broken down as follows:

• EUR 57,789.74 in membership fees and contributions
• EUR 19,500 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day).

Corporate support

In 2014, Alzheimer Europe received EUR 40,700 from corporate sources as core-funding which can be broken down as follows:

• EUR 35,000 from GlaxoSmithKline as support to the organisation’s core activities,
• EUR 5,700 from Newsweaver which provided an e-mail facility free of charge.

Private individuals

In 2014, AE received EUR 998.56 from individuals which can be broken down as follows:

• EUR 500.50 in publication sales and
• EUR 498.06 in donations.

Bank interest and similar

In 2014, Alzheimer Europe had an income of EUR 558.22 from bank interest and similar income.

Other income

In 2014, EUR 14,439.97 came from other sources not mentioned above.

Funding of project activities (EUR 545,126.66)

In 2014, Alzheimer Europe received EUR 545,126.66 for its various projects, including its Annual Conference in Glasgow, Scotland, a project on good incontinence care and its corporate affairs activities, of which

• EUR 261,607.70 (47.99%) came from corporate sponsors

• EUR 164,362.24 (30.15%) from private individuals,
• EUR 112,876.31 (20.71%) from public sources and
• EUR 9,349.29 (1.72%) from foundations and other non-profit organisations,
• EUR 5,991.13 (1.10%) from deferred income from 2013,
• EUR -9,060.19 (-1.66%) was income deferred to 2015.

Corporate support

The corporate support received by Alzheimer Europe for its activities in 2014 (EUR 261,607.70) can be broken down as follows:

• Lilly contributed EUR 51,891.33 as a gold sponsor of AE’s corporate programme and AE’s Annual Conference in Glasgow, and as travel support,
• SCA Global Hygiene contributed EUR 41,500 as a bronze sponsor of AE’s corporate programme, as a silver sponsor of AE’s Annual Conference and towards the AE/SCA joint project on good incontinence care,
• Hoffmann-LaRoche contributed EUR 20,283.92 as a bronze sponsor of AE’s corporate programme, as a silver sponsor of AE’s Annual Conference in Glasgow and as travel support,
• Piramal provided EUR 15,000 as a bronze sponsor of AE’s corporate programme and AE’s Annual Conference in Glasgow,
• Lundbeck provided EUR 10,432.45 as a bronze sponsor of AE’s corporate programme and as travel support,
• Janssen and Danone contributed EUR 20,000 each as silver sponsors of AE’s corporate programme,
• Pfizer, Novartis, GE Healthcare and Merz contributed EUR 10,000 as bronze sponsors of AE’s corporate programme,
• Nestec provided EUR 7,500 as a sponsor of AE’s corporate programme,
• Sandoz provided EUR 5,000 as a sponsor of AE’s corporate programme
• Kaizo contributed EUR 20,000 as a sponsor of a networking event at AE’s Annual Conference in Glasgow,
• Bupa contributed EUR 10,000 as a sponsor of a networking event at AE’s Annual Conference in Glasgow.

Private individuals

In 2014, Alzheimer Europe received EUR 164,362.24 in registration fees for the Alzheimer Europe Conference in Glasgow.

Public funding

In 2014, Alzheimer Europe received EUR 99,310.76 as a grant from the European Commission and EUR 13,565.55 from the Scottish Government for its Annual Conference in Glasgow.

Foundations and organisations

In 2014, Alzheimer Europe received EUR 9,349.29 from the Life Changes Trust in Glasgow.

Deferred income

In 2014, Alzheimer Europe was able to contribute EUR 5,991.31 to its project activities which came from deferred income in 2013 and reported EUR 9,060.19 of its project income to 2015.

Overall funding

The following table lists all sources of income received in 2014.

In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.